CNTX Research | Milton Maxwell

CNTX

Context Therapeutics Inc.

1.1000

-0.0300-2.65%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

101.07M

P/E (TTM)

Basic EPS (TTM)

-0.24

Dividend Yield

Recent Filings

8-K

11/5/25Nov 5, 2025

10-Q

11/5/25Nov 5, 2025

8-K

Nasdaq compliance regained

10/20/25Oct 20, 2025

Context Therapeutics Inc. regained compliance with Nasdaq's Minimum Bid Price Rule on October 17, 2025, after its common stock closed at $1.00 or higher for 10 consecutive business days. This resolves the deficiency flagged in February 2025 and extended through February 2026. Nasdaq now deems the matter closed. Investors breathe easier.

8-K

Nasdaq grants bid price extension

9/2/25Sep 2, 2025

Context Therapeutics received a Nasdaq extension on August 28, 2025, granting 180 days until February 23, 2026, to lift its common stock above $1.00 per share and comply with the Minimum Bid Price Rule. The notice follows a February 27, 2025, deficiency alert after 30 days below the threshold. No immediate trading disruption. The company eyes a reverse stock split but offers no compliance guarantee.

10-Q

Q2 FY2025 results

8/6/25Aug 6, 2025

Context Therapeutics ramped up R&D spending in Q2 FY2025 ended June 30, 2025, with operating expenses hitting $9.8M, up 216% y/y from $3.1M, driven by new programs in CT-95 and CT-202 alongside CTIM-76; net loss widened to $8.8M from $2.3M y/y, or $0.09 per diluted share on 95.2M shares, while interest income edged up 8% to $0.9M on higher cash balances. YTD through June, R&D costs climbed 236% to $11.3M, fueling a $13.4M net loss versus $5.9M last year, with cash burn at $10.9M from operations. Cash stood at $83.5M, sufficient into 2027 for Phase 1 dose escalations in CTIM-76 and CT-95, plus CT-202 trial prep—no debt, no FCF disclosed. Recent asset buys bolstered the pipeline: CT-95 acquired July 2024 for $3.75M cash, CT-202 licensed September 2024 for $11.0M upfront. Yet regulatory shifts at HHS and FDA could delay approvals.

About

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CEO

Mr. Martin A. Lehr

IPO

10/20/2021

Website

https://www.contexttherapeutics.com

Employees

Sector

Healthcare

Industry

Biotechnology